15-Year Experience of <sup>18</sup>F-FDG PET Imaging in Response Assessment and Restaging After Definitive Treatment of Merkel Cell Carcinoma

Byrne, Keelan; Chait, Lori; Callahan, Jason; Bressel, Mathias; Seel, Matthew; MacManus, Michael; Hicks, Rodney J.

doi:10.2967/jnumed.115.158261

Cited by 26 publications

(25 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In other larger studies, CMR is highly prognostic for survival with a 68% 5‐year survival compared to 15% 1 year survival in those who did not achieve it. In addition, restaging PET had a high and medium impact on management in 45% and 11% respectively . Assessing the burden of metastatic disease may be important in the context of the recent trials with high response rates using where control varies with burden of metastatic disease .…”

Section: Discussionmentioning

confidence: 99%

“…In addition, restaging PET had a high and medium impact on management in 45% and 11% respectively. 12 Assessing the burden of metastatic disease may be important in the context of Merkel cell carcinoma the recent trials with high response rates using where control varies with burden of metastatic disease. 13 Further research into the areas of early detection of metastatic disease and assessment of disease burden in the era of immunotherapy are required.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Prospective analysis of the utility of 18‐FDG PET in Merkel cell carcinoma of the skin: A Trans Tasman Radiation Oncology Group Study, TROG 09:03

et al. 2018

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Prospective analysis of the utility of 18‐FDG PET in Merkel cell carcinoma of the skin: A Trans Tasman Radiation Oncology Group Study, TROG 09:03

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Diagnostic tests shall include those employed in the diagnosis of melanoma. While current data calls for using 18 F‐FDG PET/CT as primary modality , it is important to ascertain in advance whether this procedure will be covered by health insurance funds in an outpatient setting. Should this imaging technique not be available, the initial diagnostic workup shall include CT of the thorax and abdomen as well as cranial MRI .…”

Section: Diagnosismentioning

confidence: 99%

“…Zur Ausbreitungsdiagnostik sollen in Analogie zum malignen Melanom Schnittbildverfahren eingesetzt werden. Die aktuelle Datenlage spricht für den primären Einsatz der 18 F-FDG-PET/CT [8,[50][51][52][53][54][55][56], allerdings sollte die Kostenübernahme im ambulanten Bereich vorab geklärt werden. Sofern dies nicht zur Verfügung steht, soll die initiale Ausbreitungsdiagnostik ein CT-Thorax/Abdomen und MRT-Schädel beinhalten [57].…”

Section: Ausbreitungsdiagnostik Bei Erstdiagnoseunclassified

S2k guidelines for Merkel cell carcinoma (MCC, neuroendocrine carcinoma of the skin) – update 2018

Becker

Eigentler

Frerich

et al. 2019

J Deutsche Derma Gesell

View full text Add to dashboard Cite

Summary Merkel cell carcinoma (MCC, ICD‐O M8247 / 3) is a rare malignant primary skin tumor with epithelial and neuroendocrine differentiation. The neoplastic cells share many morphological, immunohistochemical and ultrastructural characteristics with Merkel cells of the skin. The diagnosis of MCC is rarely made on clinical grounds. Histological and immunohistochemical studies are usually required to confirm the clinical suspicion. Given the frequent occurrence of occult lymph node metastasis, sentinel lymph node biopsy should be performed once distant metastasis has been ruled out by cross‐sectional imaging. Primary tumors without evidence of organ metastases are treated with complete surgical excision with appropriate surgical margins. Radiation therapy should be considered at all stages of the disease. For advanced MCC that is no longer amenable to curative treatment by surgery or radiation therapy, there is currently no established systemic therapy for which an improvement in recurrence‐free survival or overall survival has been demonstrated in a prospective randomized trial. However, immunotherapy using PD‐1/PD‐L1 blockade seems to be superior to chemotherapy. Various factors warrant that further diagnostic and therapeutic interventions be determined by an interdisciplinary tumor board. These factors include the tumor's aggressiveness, the frequent indication for sentinel lymph node biopsy along with the frequent occurrence in the head and neck region, the potential indication for adjuvant radiation therapy as well as the complexity of the required diagnostic workup.

show abstract

“…Zur Ausbreitungsdiagnostik sollen in Analogie zum malignen Melanom Schnittbildverfahren eingesetzt werden. Die aktuelle Datenlage spricht für den primären Einsatz der 18 F‐FDG‐PET/CT , allerdings sollte die Kostenübernahme im ambulanten Bereich vorab geklärt werden. Sofern dies nicht zur Verfügung steht, soll die initiale Ausbreitungsdiagnostik ein CT‐Thorax/Abdomen und MRT‐Schädel beinhalten .…”

Section: Diagnostikunclassified

S2k‐Leitlinie Merkelzellkarzinom (MZK, MCC, neuroendokrines Karzinom der Haut) – Update 2018

Becker

Eigentler

Frerich

et al. 2019

J Deutsche Derma Gesell

View full text Add to dashboard Cite

Zusammenfassung Das Merkelzellkarzinom (MCC, ICD‐O M8247/3) ist ein seltener, maligner, primärer Hauttumor mit epithelialer und neuroendokriner Differenzierung. Die Tumorzellen teilen viele morphologische, immunhistochemische und ultrastrukturelle Eigenschaften mit den Merkelzellen der Haut. Die Diagnose MCC wird selten klinisch gestellt. Erst histologisch und immunhistochemisch wird der Verdacht auf ein MCC bestätigt. Nachdem eine Fernmetastasierung durch Bildgebung mit Schnittbildverfahren ausgeschlossen worden ist, sollte aufgrund der hohen Zahl von okkulten Lymphknotenmetastasen eine Schildwächterlymphknotenbiopsie erfolgen. Bei Primärtumoren ohne Hinweise auf das Vorliegen von Organmetastasen soll eine vollständige chirurgische Exzision mit Sicherheitsabstand erfolgen. Die strahlentherapeutische Behandlung sollte in allen Stadien der Tumorerkrankung in Betracht gezogen werden. Für das fortgeschrittene, operative oder strahlentherapeutische nicht mehr kurativ behandelbare MCC gibt es bisher keine etablierte systemische Therapie, für die in einer prospektiv‐randomisierten Studie eine Verbesserung des rezidivfreien Überlebens oder des Gesamtüberlebens demonstriert werden konnte. Eine Immuntherapie mittels PD‐1/PD‐L1‐Blockade erscheint aber einer Chemotherapie überlegen zu sein. Aufgrund seiner Aggressivität, der in der Regel gegebenen Indikation zur Schildwächterlymphknotenbiopsie bei gleichzeitig häufiger Lokalisation im Kopf‐Hals‐Bereich, der zu evaluierenden Indikation einer adjuvanten Radiotherapie sowie der Komplexität der notwendigen Diagnostik zur korrekten Prognoseabschätzung soll das Vorgehen im Rahmen einer interdisziplinären Zusammenarbeit (interdisziplinäres Tumorboard) festgelegt werden.

show abstract

15-Year Experience of ¹⁸F-FDG PET Imaging in Response Assessment and Restaging After Definitive Treatment of Merkel Cell Carcinoma

Cited by 26 publications

References 24 publications

Prospective analysis of the utility of 18‐FDG PET in Merkel cell carcinoma of the skin: A Trans Tasman Radiation Oncology Group Study, TROG 09:03

Prospective analysis of the utility of 18‐FDG PET in Merkel cell carcinoma of the skin: A Trans Tasman Radiation Oncology Group Study, TROG 09:03

S2k guidelines for Merkel cell carcinoma (MCC, neuroendocrine carcinoma of the skin) – update 2018

S2k‐Leitlinie Merkelzellkarzinom (MZK, MCC, neuroendokrines Karzinom der Haut) – Update 2018

Contact Info

Product

Resources

About

15-Year Experience of 18F-FDG PET Imaging in Response Assessment and Restaging After Definitive Treatment of Merkel Cell Carcinoma

Cited by 26 publications

References 24 publications

Prospective analysis of the utility of 18‐FDG PET in Merkel cell carcinoma of the skin: A Trans Tasman Radiation Oncology Group Study, TROG 09:03

Prospective analysis of the utility of 18‐FDG PET in Merkel cell carcinoma of the skin: A Trans Tasman Radiation Oncology Group Study, TROG 09:03

S2k guidelines for Merkel cell carcinoma (MCC, neuroendocrine carcinoma of the skin) – update 2018

S2k‐Leitlinie Merkelzellkarzinom (MZK, MCC, neuroendokrines Karzinom der Haut) – Update 2018

Contact Info

Product

Resources

About

15-Year Experience of ¹⁸F-FDG PET Imaging in Response Assessment and Restaging After Definitive Treatment of Merkel Cell Carcinoma